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Background: Percutaneous microwave coagulation (PMC) has been accepted as a promising modality in the
treatment of tumors in well-vascularized tissues such as liver tumors and hysteromyoma. However, PMC for
treatment of tumors in low blood-flow tissues has been seldom reported. The aim of this study was to determine
the feasibility and safety of PMC for the treatment of tumors in low blood-flow tissues in a rabbit model.
Methods: Fifteen rabbits with VX2 tumors implanted subcutaneously underneath the right second nipple were
divided into a PMC group (n = 9) and a control group (n = 6). PMC was performed with output power of 40 W for
one to two minutes. The therapeutic efficacy was evaluated by magnetic resonance imaging (MRI), physical
examinations, survival rate, and histology. The cosmetic outcome after PMC was also assessed.
Results: In the PMC group, tumor eradication was achieved in six rabbits (66.7%) without any evidence of tumor
recurrence and metastasis as proven by MRI and histological examinations. The mean greatest and shortest tumor
diameters of these six rabbits were 1.83 and 1.33 cm, respectively. Slight epidermal burns, which proved reversible,
were found in seven rabbits (77.8%). The PMC group had a significantly longer survival than those in the control
group (P= 0.0097). The four rabbits with coagulated tumors survived more than three months with their tumors
becoming nonpalpable and undetectable by MRI and histological examinations.
Conclusions: PMC is feasible and safe in the treatment of tumors in low blood-flow tissues in a rabbit model.
Attention should be paid to avoid skin burns with PMC.
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Minimally invasive therapies, including radiofrequency ab-
lation (RFA), cryotherapy, high-intensity focused ultra-
sound, and laser therapy, have been widely used in the
treatment of solitary tumors [1-5]. Due to the advantages
of favorable efficacy, low complication rates and optional
use of multiple antennae, RFA is the currently widely used
thermal ablation technique [6,7]. Percutaneous microwave
coagulation (PMC), a new promising modality, has been
used in the treatment of hepatic tumors as an effective
therapy [8-10]. Compared to other minimally invasive ther-
apies, PMC is simpler to operate and has a higher potential* Correspondence: ws0801@hotmail.com
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reproduction in any medium, provided the orfor complete tumor ablation with many advantages
[8,11,12], such as improved convection profile, consistent
higher intratumoral temperature, larger ablation volume,
and shorter ablation time. Previous studies [8,12,13]
reported that a large volume (maximum size >3cm) can
be ablated by PMC in vivo with high power outputs (≥60
W at 2,450 MHz). In addition, the temperature at the site
5 mm away from the electrode was higher with microwave
compared with RFA [12]. Therefore, PMC may elevate the
temperature more quickly in a shorter time for complete
tumor ablation.
The blood-flow is known to affect the efficacy of min-
imally invasive therapies. Theoretically, a larger volume
of ablation can be achieved in low blood-flow tissues
relative to high blood-flow tissues. In fact, high output
power (60–80 W) has been widely used in the treatmenttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ample, PMC typically used high (60–80 W) power outputs
for the treatment of tumors in well-vascularized tissues
such as liver tumors and hysteromyoma [9,13,16]. How-
ever, PMC in the treatment of tumors in low blood-flow
tissues has not been reported. Obviously, PMC using high
(60–80 W) power outputs in low blood-flow tissues may
cause more serious injuries to surrounding tissues. More-
over, low blood-flow can affect the evolution of the ablated
tumors. For example, the palpable ablated mass in the
breast after minimally invasive therapies for a long period
of time will cause discomfort and anxiety to patients
[17,18]. Detailed information about ablated tumors in low
blood-flow tissues, including the breast, is not very clear.
Other minimally invasive therapies [19-22] have been
attempted to ablate tumors in low blood-flow tissue includ-
ing the breast. Previous study [23] showed the usefulness of
microwave coagulation to breast cancer ex vivo. The VX2
tumor model is a widely used animal tumor model for min-
imally invasive therapies [24-29]. We implanted the VX2
tumors subcutaneously underneath the right second nipple
in rabbits to investigate whether a relatively low output
power 60 W at 2,450 MHz was suitable for ablating the
tumors in low blood-flow tissues. However, serious burns
to the skin and muscles were observed in our preliminary
experiment. The aim of this study was to determine the
feasibility and safety of PMC with a lower output power
(40 W at 2,450 MHz) for the treatment of tumors in low-
blood flow tissues. The evolution of PMC ablated tumors
in low-blood flow tissues was also assessed.Methods
Tumor model
Animal experiments were approved by the Animal Care
and Use Subcommittee at our University. Adult female
New Zealand White rabbits weighing between 2.0 and
3.0 kg were used in this study. The VX2 cell line, used
for tumor implantation, was obtained from the Surgery
Department of our Hospital. The rabbits were anesthe-
tized using an intravenous injection of pentobarbital
(30 mg/mL, 0.8 to 1.2 mL/kg, pentobarbital sodium;
Sigma, St, Louis, MO, USA) before the VX2 tumor in-
oculation and other procedures. The required tumor tis-
sue, taken from a tumor carrier rabbit, was cut into
small strips (1.5 × 1.5 × 6 mm). Each strip of tumor tissue
was inserted subcutaneously underneath the right sec-
ond nipple by a 16-gauge needle. The animals were fol-
lowed up every week by physical examination. The
tumor growth was 100% in the implantation sites. When
the animals refused solid and fluid intake for more than
four days with concomitant apathy and weight loss of
more than 20%, the animals were sacrificed for ethical
reasons [29].Experimental groups
The larger and shorter diameters of the tumor were
measured using a caliper. After the larger diameter of
the tumor reached about 15 mm (10 to 21 days), 15
rabbits were included in this study with the following
treatments: PMC group (n = 9), nine rabbits with nine
VX2 tumors were treated with PMC and control group
(n = 6), six rabbits with six VX2 tumors served as un-
treated controls.PMC protocol
After the same anesthesia as in tumor implantation, the
rabbits were positioned supine. The cooled-shaft antenna
(2 mm in diameter) was inserted into the tumor along the
long axis without any navigation. This microwave delivery
system consists of a microwave generator, a flexible coaxial
cable and an internally-water-cooled-shaft antenna. The
microwave irradiation frequency is 2,450 MHz. An output
power of 40 W was chosen in this study. After testing the
cold water (4°C) cycling system, the PMC procedure was
started for one to two minutes to eradication of the entire
tumor according to the tumor size [8,11-13] and our own
experience. Since the larger diameter of all the tumors was
less than 2.5 cm, two minutes may be enough. Therefore,
when the shorter diameter of the tumor was shorter than
1.5 cm, one minute was chosen. When the shorter diam-
eter of the tumor was shorter than 2.0 cm, one and a half
minutes was used. When the shorter diameter of the
tumor was shorter than 2.5 cm, two minutes was chosen
in our study.
After PMC treatment, the antenna was removed and the
incision closed. All the rabbits were monitored during the
PMC treatment and for one month after surgery for any
complications that might be induced by the intervention.
The degree and extension of the burns to the skin were
evaluated. The behavior of the rabbits after the treatment
was observed. Furthermore, the weight and food intake of
the rabbits were monitored.Therapeutic evaluation
The efficacy of PMC therapy was evaluated with survival
rate, MRI, physical examination of the coagulated tumors
and histopathology. MRI was performed to monitor the
long-term results of the coagulated tumors at day 0, week
1, week 3 and week 7 after PMC therapy. Core needle bi-
opsy was randomly performed on two rabbits for histo-
logical examination at week 1 and week 3 after PMC
therapy. Since there was little tissue under the skin at week
7, core needle biopsy was not performed at this time-point
. Incomplete ablation was determined by core needle bi-
opsy or MRI follow-up without treatment control. When
the tumors were not reabsorbed with local growth or the
needle biopsies were positive, the tumors were recognized
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the therapeutic effect between the two groups.
MRI follow-up
Prior to MRI scanning, the animals were anesthetized by
the procedure described as in tumor implantation to
decrease respiratory rates for clear images. The animals
were strapped but not intubated to reduce motion artifacts.
Respiratory-triggered sequence with prospective acquisition
correction was applied to MRI examination for respiration
control. Rabbits in the PMC group were subject to three
Tesla (T) MRI examinations (Trio, Siemens Healthcare) at
pre-microwave therapy, one week, three weeks and seven
weeks post-PMC therapy. T2-weighted 2D fast spin-echo
(FSE) sequences were acquired in the axial plane using a
phased-array coil. The 2D FSE sequence was performed
with the following parameters: TR, 3,948 to 4,960 millise-
conds; TE, 80 to 89 milliseconds; matrix size (168 to
256) ×320; field of view, (135 to 150) × (150 to 180) mm;
slice thickness, 4 mm; bandwidth, 205 to 260 Hz; and
acquisition time, 104 to 150 seconds. The techniques of
MRI were the same during the procedure.
Histopathological examination
The animals were autopsied within six hours after death.
The tissue specimens were fixed in 10% formalin solution,
embedded in paraffin, sectioned into 4 μm slices, and
stained with H & E. The histological slides were evaluated
by one experienced pathologist.
Statistics
The numerical data were reported as mean ± standard
deviation (SD). Survival curves were generated using the
Kaplan-Meier method. The log-rank test was used to
compare mean survival between the two groups. All P-
values were two-tailed with 5% significance levels. All stat-
istical analyses were performed using STATA version 11.0
(Computer Resource Center, America).
Results
General aspects
All rabbits in the PMC and control groups tolerated the
experimental procedures. All the animals recovered well
after the experiment. Although output power was only 40
W, epidermal burns, measuring 0.5 to approximately 1 cm
in the greatest dimension, were found in seven rabbits in
the PMC group. However, no necrosis of the skin was
observed. Due to a high rate (7/9, 77.8%) of epidermalTable 1 Summary of PMC tumor ablation effects in the breas
Group No. animals Local growth Metastasis
PMC 9 3 2
Control 6 6 6burns, it seems a very likely occurrence. No other immedi-
ate adverse effects occurred in all rabbits. Only about ten
minutes was needed for the total PMC procedure.
Tumor eradication effect
The detailed information is shown in Table 1. The rabbits
in the control group without PMC therapy died of end-
stage malignancies (mean 47.7 ±14.2 days). Five rabbits in
the control group showed pulmonary metastases (Figure 1).
In the PMC group, the mean greatest diameter of the
tumor was 1.72±0.36 cm (range, 1.5 to 2.5 cm) before
PMC therapy. The mean coagulation time was 1.06±0.17
minutes (range, 1.0 to 1.5 minutes). Tumor eradication was
achieved in six rabbits (66.7%) without any evidence of
tumor recurrence and metastasis. The mean greatest tumor
diameter of these six rabbits was 1.83±0.41 cm (range, 1.5
to 2.5 cm), and the short diameter was 1.33±0.41 cm
(range, 1.0 to 2.0 cm) before PMC treatment. Of these six
rabbits, two rabbits died on the 16th and 34th day after
PMC therapy without evidence of tumor recurrence or me-
tastasis. An infectious disease, which may be caused by the
PMC therapy, induced the death on day 16 after PMC
treatment. Diarrhea, which is one of the most common
causes of death in immature rabbits, induced the death on
day 34 after PMC therapy. The other four rabbits survived
longer than three months free of disease, of which three
rabbits survived longer than six months. In contrast, no
rabbits in the control group survived longer than 70 days.
Survival analysis showed that rabbits in the PMC group
had a significantly higher survival than those in control
group (P=0.0097) (Figure 2).
Physical examination and MRI findings
Tumor palpability was evaluated by physical examination
every week. One week after PMC, the size of the ablated
area was larger than before. Except for three rabbits with
local recurrence, the tumors treated with PMC in the
other six rabbits were progressively absorbed. Of these six
rabbits, four survived longer than three months. All the
tumors of these four rabbits became nonpalpable in three
months after PMC therapy. The epidermal burns in the
rabbits were healed after approximately 2 to 3 weeks.
Progressive resorption was also detected by MRI. The
details are shown in Figure 3. In accordance with physical
examinations, the image at one week (Figure 3B) after
PMC therapy showed obvious edema and hyperemia
around the coagulated tumor. At week three after PMC
therapy (Figure 3C), the edema and hyperemia of the lesiont
Eradication Eradication rate (%) Survive >3 months
6 66.7 4
0 0 0
Figure 1 One case with lung metastases. A) Macroscopic appearances of the lungs with metastatic nodules; B) Metastatic nodules
demonstrated by hematoxylin and eosin (H&E) stain (10 ×).
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was much smaller than that at week one. The coagulated
VX2 tumor was absorbed completely at week seven after
PMC therapy (Figure 3D).
Local recurrence was detected in three rabbits in the
PMC group by MRI (Figure 4). At one week after PMC
therapy, no obvious local recurrence was detected by
physical examination and MRI (Figure 4B) due to obvious
edema and hyperemia. However, local recurrence was
detected by MRI at week three after PMC therapy, but it
was not very clear (Figure 4C). At week seven after PMC
therapy, local recurrence was very obvious (Figure 4D). Of
these three rabbits with local recurrence, metastases wereFigure 2 Graph of Kaplan-Meier survival analysis showed that rabbits
than those in the control group.observed in two rabbits. The first metastasis was detected
by MRI 35 days after PMC therapy.
Histopathological examination
Histologically, the coagulated tissues appeared almost
unchanged after PMC therapy, especially at week one
(Figure 5A). At the H & E staining, the coagulated
tumors looked almost intact in tissue architecture and
were stained a little lighter than viable tissues. The out-
line of the coagulated tumor cells was still clear, but the
nuclei were fractured. Some apoptotic bodies were
observed in the area, the coagulation of which was insuf-
ficient. The cell architecture in the viable area wasin the PMC-treated group had a significantly higher survival
Figure 3 Magnetic resonance (MR) images from a rabbit with a VX2 tumor before and after PMC therapy. A) Image obtained before
microwave therapy; B) Image obtained one week after PMC therapy: edema and hyperemia of lesion is obvious; C) Image obtained three weeks
after microwave therapy: most part of the ablated tumor was absorbed; D) Image obtained seven weeks after microwave therapy: the ablated
tumor was absorbed completely to nonpalpable.
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between the coagulated tumors and viable tissues was
more obvious at week three than week one (Figure 5). A
sharper demarcation between the coagulated tumors and
viable tissues was observed at week three after PMC
therapy than at week one.
Discussion
The present study first reported a successful experience of
PMC with a low output power (40 W at 2450 MHz) in the
treatment of VX2 tumors in low blood-flow tissues. Our
results suggest that PMC with a low output power (40 W)
is feasible in the treatment of tumors in low blood-flow
tissues. However, slight epidermal burns without necrosis
of the skin were still found. Furthermore, the ablatedtumors were well absorbed to nonpalpable in low blood-
flow tissues.
RFA has been widely used in the treatment of different
tumors in VX2 tumor models [25-27,29]. Previous studies
suggested rabbits in RFA-treated groups survived longer
than those in control groups. We first reported PMC in the
treatment of tumor implantations subcutaneously under-
neath the right second nipple in rabbits, one kind of low
blood-flow tissues. Although the VX2 tumor cell line is
known for its malignant potential and ability to metastasize
early, the same encouraging results were still observed in
this study. In the PMC group, three of nine rabbits with
local recurrence showed incomplete ablation, determined
by core needle biopsy or MRI follow-up assessment with-
out treatment control. However, six other rabbits, that
Figure 4 Magnetic resonance (MR) images from a rabbit with local recurrence after PMC therapy. A) Image obtained before microwave
therapy: a tumor beneath the skin; B) Image obtained one week after PMC therapy: obvious edema and hyperemia around the ablated tumor
was observed; C) Image obtained three weeks after microwave therapy: the ablated tumor was partly absorbed; however, local recurrence (arrow)
was detected although it was not very clear; D) Image obtained seven weeks after microwave therapy: most of the ablated tumor was absorbed;
however, obvious local recurrence (arrow) was detected.
Figure 5 Photomicrographs from coagulated VX2 tumor and viable tumor stained with H & E at week one (A) and week three (B).
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Future studies should be carried out to confirm this inter-
esting finding in clinic.
Although the output power was low in this study, skin
burns were still observed in seven rabbits in the PMC
group. The burns were caused by a non controlled expos-
ure that heated surrounding tissues that had a low flow
and, therefore, burned easily. Therefore, burns to the
tissues around the tumor should be considered when PMC
is used, especially for tumors in low blood-flow tissues. For
example, to avoid burns in the skin or pectoralis major
muscle, the distance from the breast tumor to the skin and
pectoralis major muscle should be considered. According
to previous studies [30,31], a distance of at least 1 cm be-
tween the tumor and the skin and between the tumor and
the chest wall is required. Whether this criterion is suitable
for PMC in the treatment of small breast cancers should
be confirmed. In addition, a previous study [32] suggested
that the extension of microwave exposure could be con-
trolled by using MR thermometry. The microwave gener-
ator at 2,450 MHz did not interfere with MR images.
Therefore, MR thermometry can be used to control the
temperature at the target level for PMC therapy. However,
the VX2 tumors were easy to target and MR was not used
for navigation in this study. For clinical accuracy and safety,
future studies should be undertaken to determine the role
of MR thermometry in PMC therapy.
PMC has gradually been accepted as a promising new
modality for tumor ablation, with many advantages. In our
study, only about one minute was used for complete abla-
tion. The treatment time was far less than other minimally
invasive therapies [28,33]. In addition, PMC was simpler to
operate compared with other minimally invasive therapies.
Only about ten minutes was needed in total for the therapy
procedures in our study. Our results suggest that PMC
with a low output power may be a promising modality for
the treatment of tumors in low blood-flow tissues.
Although our results are encouraging, several concerns
should be considered for clinical practice of PMC in the
treatment of tumors in low blood-flow tissues including
breast cancers. First, for complete ablation with a rela-
tively low output power, tumors of a large size should be
excluded. Second, the guidance of the antenna is import-
ant for accurate placement. Third, the monitoring of the
procedure is also important. Future clinical studies are
needed to confirm our encouraging results.
Several limitations still existed in this study. First,
the VX2 tumors were present beneath the skin,
which enabled us to accurately target the tumor and
control the lesion size. Second, since no rabbit-
specific coils or scanner was used for the MRI scan-
ning, the images were not very clear. Not using any
technique to control complete ablation right after
the treatment was an important limitation to thetechnique since the potential for relapse is high and
can only be ascertained after the relapse occurs.
Contrast enhanced imaging should be used to deter-
mine whether the whole tumor is ablated in the
future. Third, although rabbits in the PMC group
survived significantly longer than those in the
control group, future studies with a large sample size
are still needed to confirm our encouraging results.Conclusions
The results of this study have demonstrated the
feasibility of PMC in treating VX2 tumors in low
blood-flow tissues. However, slight epidermal burns
without necrosis of the skin, which proved revers-
ible, were still found. PMC was effective and safe in
the treatment of tumors in low blood-flow tissues.
After microwave coagulation, the tumors were well
absorbed to nonpalpable in low blood-flow tissues.
Future clinical studies are required to validate the
use of this technique in the treatment of tumors in
low blood-flow tissues including breast cancers and
metastatic tumors subcutaneously.
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